Ref. | Immunotherapy | Primary tumor | Bone marrow biopsy | Neurology symptoms | Treatment | Clinical outcomes |
---|---|---|---|---|---|---|
[4] | Nivolumab | NSCLC | + | No | Steroids | Improvement |
[5] | Nivolumab/ Ipilimumab/ Avelumab (3 cases, monotherapy) | Melanoma/ Merkel cell carcinoma | +/− | Unknown | Steroids | Death/ improvement |
[6] | Pembrolizumab | Bladder carcinoma | + | Unknown | Steroids and etoposide | Unknown |
[7] | Ipilimumab and nivolumab | Melanoma | Not done | No | Steroids and mycophenolate mofetil | Improvement |
[8] | Pembrolizumab | Melanoma | Not done | No | Steroids | Improvement |
[9] | Ipilimumab and nivolumab | Melanoma | + | No | Steroids | Improvement |
[10] | BRAF inhibitors sequential after pembrolizumab | Melanoma | Not done | No | Steroids | Improvement |
[11] | Ipilimumab sequential after pembrolizumab | Melanoma | + | No | Steroids and etoposide | Death |
[12] | Pembrolizumab | NSCLC | + | No | Steroids | Improvement |
[13] | Nivolumab | NSCLC | Not done | No | Steroids and mycophenolate mofetil | Improvement |
[14] | Pembrolizumab | Thymic cancer | + | Yes | Steroids, IVIG, anakinra | Death |
[15] | Pembrolizumab | Prostate cancer | + | No | Steroids+ plasmapheresis + etoposide + tacrolimus | Improvement |
[16] | Pembrolizumab | Breast cancer | Not done | No | Steroids | Improvement |
[17] | Nivolumab and anti-IDO | Glioblastoma | + | Yes | Steroids | Death |
[18] | Pembrolizumab | Head and neck | + | No | Steroids and etoposide | Improvement |
[19] | Pembrolizumab | NSCLC | + | No | Steroids | Improvement |
[20] | Ipilimumab and nivolumab | Melanoma | + | No | Steroids, tocilizumab | Improvement[ |
[21] | Pembrolizumab | Pulmonary sarcomatoid carcinoma | Not done | No | Steroids | Death |
[21] | Ipilimumab + nivolumab | Melanoma | Not done | No | Steroids + etoposide + IVIG + tocilizumab | Improvement |
[21] | Ipilimumab + nivolumab | Melanoma | + | No | Steroids + etoposide | Death |
[21] | Ipilimumab + nivolumab | Melanoma | − | No | Steroids | Improvement |
[21] | Ipilimumab + nivolumab | Melanoma | + | No | Steroids | Improvement |
[22] | Atezolizumab + chemotherapy | NSCLC | + | No | Steroids | Improvement |
[23] | Pembrolizumab | NSCLC | + | No | Steroids | Improvement |
[24] | Pembrolizumab | NSCLC | + | No | Steroids | Improvement |
[24] | Pembrolizumab | NSCLC | Not done | No | Steroids | Improvement |
[25] | Pembrolizumab | NSCLC | + | No | Steroids + etoposide | Improvement |